Abstract Details

Title AI-driven Evaluation of PIRA and Treatment Efficacy in Multiple Sclerosis: Insights from the BeCare MS App

Topic Multiple Sclerosis

Presentation(s) P4 - Poster Session 4 (5:00 PM-6:00 PM)

Poster/Presentation
Number 1-001

Objective
This study evaluates the efficacy of the BeCare MS mobile app in detecting neurologic changes in patients treated with low efficacy versus high efficacy therapeutics.

Background
Multiple sclerosis (MS) is a leading cause of disability among working-age individuals. Despite over 25 approved disease-modifying therapies (DMTs), disease progression remains a significant concern. Recently, Progression Independent of Relapse Activity (PIRA) has emerged as a critical treatment goal, underscoring the need for more efficient and quantitative measures of disability.

Design/Methods

We conducted a retrospective review of data from over 7,000 BeCare MS app users. The app uses phone sensors and questionnaires to quantitatively measure neurologic dysfunction and disability scores (EDSS). Gamified activities reflect assessments typically performed in MS clinics, measuring cognitive skills across four domains: memory, processing speed, executive function, and language. Users completed various tests, including fine motor and the 25-foot walk, contributing to the calculation of population percentiles based on performance.

Results
We compared improvements in performance between low efficacy treatments (interferons, Glatiramer Acetate, and Teriflunomide) and high efficacy treatments (anti-CD20 MABs and S1P modulators) over a minimum of 90 days. Of 162 users in the low efficacy group and 224 in the high efficacy group, many were excluded due to insufficient data. Improvement, defined as increased population scores over time, was observed in both groups. Specifically, 36% of low efficacy users improved in the fine motor testing compared to 44% in the high efficacy group. Additionally, 33% of low efficacy users showed improvement in the 25-foot walk, compared to 37% in the high efficacy group.

Conclusions
Patients using high efficacy therapies demonstrated greater improvement than those on low efficacy treatments. While the study is limited by app usage frequency and sample size, it highlights the BeCare MS App's potential as a digital tool for assessing performance and quantifying disability in MS patients, including PIRA.

Authors/Disclosures
Sharon Stoll, DO (Stoll Medical Group) PRESENTER	Dr. Stoll has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for roche Genentech. Dr. Stoll has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche/Genentech . Dr. Stoll has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for biogen. Dr. Stoll has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for novartis. Dr. Stoll has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for sanofi/genzyme. Dr. Stoll has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion. Dr. Stoll has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for BMS. Dr. Stoll has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Horizon. Dr. Stoll has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for TG Therapeutics . Dr. Stoll has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for EMD Serono . Dr. Stoll has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Dr. Stoll has received personal compensation in the range of $50,000-$99,999 for serving on a Speakers Bureau for Biogen. Dr. Stoll has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Sanofi Genzyme. Dr. Stoll has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for alexion. Dr. Stoll has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for EMD Serono . Dr. Stoll has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Horizon. Dr. Stoll has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for BMS. Dr. Stoll has stock in BeCare Link LLC. Dr. Stoll has stock in Global Consult MS .
larry rubin	No disclosure on file
Charisse D. Litchman, MD	Dr. Litchman has received personal compensation for serving as an employee of BeCare . Dr. Litchman has received personal compensation in the range of $100,000-$499,999 for serving as a Consultant for Nurx. Dr. Litchman has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Allergan.

��ɫ��

��ɫ��